Glaukos (GKOS) licensed RO-104, a tri-specific biologic targeting VEGF-A, VEGF-C, and Ang-2, plus access to RevOpsis' RevMod platform for up to four additional retinal candidates. Financial terms undisclosed.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
